Cyberonics (CYBX) updated its FY13 earnings guidance on Friday. The company provided EPS guidance of $1.66-1.72 for the period, compared to the Thomson Reuters consensus EPS estimate of $1.60. The company issued revenue guidance of $248-250 million, compared to the consensus revenue estimate of $247.73 million.

Several analysts have also recently commented on the stock. Analysts at Piper Jaffray reiterated an overweight rating on shares of Cyberonics in a research note to investors on Monday, February 4th. They now have a $55.00 price target on the stock. On a related note, analysts at Sidoti upgraded shares of Cyberonics from a neutral rating to a buy rating in a research note to investors on Wednesday, January 23rd. Finally, analysts at Zacks reiterated an outperform rating on shares of Cyberonics in a research note to investors on Thursday, November 29th. They now have a $63.00 price target on the stock.

Eight research analysts have rated the stock with a buy rating, one has issued a hold rating, and one has assigned a sell rating to the company’s stock. The company has a consensus rating of overweight and a consensus target price of $55.12.

Shares of Cyberonics (CYBX) opened at 44.33 on Friday. Cyberonics (CYBX) has a 52 week low of $35.31 and a 52 week high of $56.73. The stock’s 50-day moving average is currently $47.95. The company has a market cap of $1.229 billion and a P/E ratio of 29.77.

Cyberonics last issued its quarterly earnings data on Friday, February 22nd. The company reported $0.47 earnings per share for the quarter, beating the analysts’ consensus estimate of $0.38 by $0.09. The company had revenue of $62.70 million for the quarter, compared to the consensus estimate of $60.59 million. During the same quarter last year, the company posted $0.34 earnings per share. Cyberonics’s revenue was up 15.0% compared to the same quarter last year. Cyberonics has set its FY13 guidance at $1.66-1.72 EPS. On average, analysts predict that Cyberonics (CYBX) will post $1.60 earnings per share for the current fiscal year.

Cyberonics, Inc. (Cyberonics) is a neuromodulation company engaged in the design, development, sales and marketing of implantable medical devices that provide a therapy, vagus nerve stimulation therapy (VNS Therapy), for the treatment of refractory epilepsy and treatment-resistant depression.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.